Navigation Links
Mayo Clinic: New multiple myeloma treatment guidelines personalize therapy for patients
Date:4/1/2013

ROCHESTER, Minn. -- Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy. The guidelines are published in the current issue of the journal Mayo Clinic Proceedings and represent a consensus opinion of hematologists at Mayo Clinic Cancer Center sites in Minnesota, Florida and Arizona.

"Multiple myeloma is an incurable blood cancer that affects more than 20,000 people in the U.S. each year," says lead author Joseph Mikhael, M.D. a hematologist at Mayo Clinic in Arizona. "Over the past decade we have made great progress in understanding the disease, developing drug therapies and increasing overall survival. However, as a medical community we haven't done as good a job at optimizing therapy based on a patient's individual risk factors."

Dr. Mikhael says the new guidelines will help patients with low-risk disease avoid the harsh side effects of therapy and will reserve more intense therapy for patients with aggressive disease.

Among the guidelines:

  • A strong recommendation to enroll patients in clinical trials as the first option for therapy or supportive care.

  • Separating patients by risk into three groups to make the most of new drug therapy: high risk, intermediate risk and low risk. Previous guidelines included only two groups: high risk and standard risk.

  • Adding factors to assess the risk the multiple myeloma poses to the patient, including use of gene expression profiling to help identify patients with high-risk disease.

  • Greater emphasis on delaying stem cell transplants to take advantage of improved chemotherapy, resulting in better responses.

  • Maintenance therapy using drugs such as lenalidomide and bortezomib that balance benefit with short- and long-term toxicity.


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: Skin problems, joint disorders top list of reasons people visit doctors
2. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
3. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
4. Mayo Clinic: Antidepressant eases radiation-related mouth pain in head, neck cancer
5. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
6. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
7. Mayo Clinic: Common blood pressure drug linked to severe GI problems
8. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
9. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
10. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
11. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... , ... A major challenge many labs face is a direct result from ... freeze dry cycle are a few common challenges that can overcome when following best ... accessories and advancements in laboratory freeze dryers that will improve quality and reduce the ...
(Date:7/26/2017)... Bethesda, Maryland (PRWEB) , ... ... ... International Society for Pharmaceutical Engineering (ISPE) will host its 2017 Process ... September. These concurrent events offer comprehensive solutions to process validation lifecycle challenges ...
(Date:7/26/2017)... ... 26, 2017 , ... Team Type 1 Foundation, a nonprofit organization pursuing a ... diabetes, is excited to announce the 106 college athletes with type 1 diabetes who ... 2005, the Team Type 1 Foundation has bestowed a total of 271 college scholarships ...
(Date:7/26/2017)... ... July 26, 2017 , ... IDC-Eating Disorder Care ... the treatment program located in Royal Oak, Michigan. IDC, formerly known as ... focused on providing the highest standards in the field of eating disorder treatment in ...
(Date:7/26/2017)... ... ... a partner at the Andrew Cores Family Law Group, a division of Esp ... year. She will serve the membership in this capacity for a term of one year ... by-laws. , Musielak joined the Andrew Cores Family Law Group in ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... CLEVELAND , July 10, 2017  US medical ... billion in 2021, according to Medical Equipment ... released by Freedonia Focus Reports. Continued increases in demand ... the aging of the population and supported by gains ... associated equipment and supplies. New product introductions will also ...
(Date:7/10/2017)... COLUMBIA, S.C. , July 10, 2017 /PRNewswire/ ... product purchasing and patient support services organization serving ... announced today the launch of four significant, value-added ... into market insights, better manage reimbursement and improve ... Ig and factor therapies. ...
(Date:7/10/2017)... 10, 2017 Locus Biosciences Inc. today announced ... the development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the ... Chinese Internet services provider, and joined by the North ... disease product programs targeting antibiotic resistant infections and other ... by Dr. Rodolphe Barrangou and Dr. ...
Breaking Medicine Technology: